SLC12A3 and Hypertension: In the participants with YOH (cohort 1) and treatment-naïve hypertension (cohort 2), SLC12A3 rs16963397 C/C or C/G polymorphisms, SLC12A3 rs13334864 C/C or C/T polymorphisms, and SLC12A3 rs7187932 A/A or A/G polymorphisms were associated with higher eGFR than their counterparts.